Journal Articles

2020

Arthritis & Rheumatology | May 20

  • Lorecivivint, a Novel Intra‐articular CLK/DYRK1A Inhibitor and Wnt Pathway Modulator for Treatment of Knee Osteoarthritis: A Phase 2 Randomized Trial

    Arthritis & Rheumatology. doi: 10.1002/art.41315


    Yusuf Yazici, Timothy E. McAlindon, Allan Gibofsky, Nancy E. Lane, Daniel Clauw, Morgan Jones, John Bergfeld, Christopher J. Swearingen, Anita DiFrancesco, Ismail Simsek, Jeyanesh Tambiah, Marc C. Hochberg

The Spine Journal | May 12

  • A Small-Molecule Inhibitor of the Wnt Pathway, Lorecivivint (SM04690), as a Potential Disease-Modifying Agent for the Treatment of Degenerative Disc Disease

    The Spine Journal. doi: 10.1016/j.spinee.2020.04.024


    Vishal Deshmukh, PhD, Maureen Ibanez, MS, Haide Hu, PhD, Joseph Cahiwat, Ying Wei, MD, Joshua Stewart, BS, John Hood, PhD, Yusuf Yazici, MD

2019

Cancer Letters | September 24

  • The CLK inhibitor SM08502 induces anti-tumor activity and reduces Wnt pathway gene expression in gastrointestinal cancer models

    Cancer Letters. doi:10.1016/j.canlet.2019.09.009


    Betty Y.Tam, Kevin Chiu, Heekyung Chung, Carine Bossard, John Duc Nguyen, Emily Creger, Brian W. Eastman, Chi Ching Mak, Maureen Ibanez, Abdullah Ghias, Joseph Cahiwat, Long Do, Shawn Cho, Jackie Nguyen, Vishal Deshmukh, Josh Stewart, Chiao-wen Chen, Charlene Barroga, Luis Dellamary, Sunil K. KC, Timothy J. Phalen, John Hood, Steven Cha, Yusuf Yazici

Aging Cell | July 03

  • Tau pathology reduction with SM07883, a novel, potent, and selective oral DYRK1A inhibitor: A potential therapeutic for Alzheimer's disease

    Aging Cell. doi: 10.1111/acel.13000


    Benoît Melchior, Gopi Kumar Mittapalli, Carolyn Lai, Karen Duong‐Polk, Joshua Stewart, Bora Güner, Brian Hofilena, Amanda Tjitro, Scott D. Anderson, David S. Herman, Luis Dellamary, Christopher J. Swearingen, K.C. Sunil, Yusuf Yazici

Osteoarthritis and Cartilage | May 24

  • Modulation of the Wnt pathway through inhibition of CLK2 and DYRK1A by lorecivivint as a novel, potentially disease-modifying approach for knee osteoarthritis treatment

    Osteoarthritis and Cartilage. doi: 10.1016/j.joca.2019.05.006


    V. Deshmukh, A.L. O'Green, C. Bossard, T. Seo, L. Lamangan, M. Ibanez, A. Ghias, C. Lai, L. Do, S. Cho, J. Cahiwat, K. Chiu, M. Pedraza, S. Anderson, R. Harris, L. Dellamary, S. KC, C. Barroga, B. Melchior, B. Tam, S. Kennedy, J. Tambiah, J. Hood, Y. Yazici

2017

Osteoarthritis and Cartilage | September 15

Osteoarthritis and Cartilage | July 13

  • A novel Wnt pathway inhibitor, SM04690, for the treatment of moderate to severe osteoarthritis of the knee: results of a 24-week, randomized, controlled, phase 1 study

    Osteoarthritis and Cartilage, 25(10), 1598-1606. doi: 10.1016/j.joca.2017.07.006


    Y. Yazici, T.E. McAlindon, R. Fleischmann, A. Gibofsky, N.E. Lane, A.J. Kivitz, N. Skrepnik, E. Armas, C.J. Swearingen, A. DiFrancesco, J.R.S. Tambiah, J. Hood, M.C. Hochberg

  • Related Review: Osteoarthritis in 2017: Latest advances in the management of knee OA

Conferences

2020

American Association for Cancer Research (AACR) Annual Meeting | June 22 - 24

Virtual Meeting

  • SM08502, a Novel, Small-Molecule CDC-like Kinase (CLK) Inhibitor, Demonstrates Strong Antitumor Effects and Wnt Pathway Inhibition in Castration-Resistant Prostate Cancer (CRPC) Models

  • Transcriptome Analysis of TCGA Prostate Cancer Samples Identifies an Association of Poorer Survival and Aggressive Disease Biology with CDC-like Kinase (CLK) Expression and Spliceosome Regulation

  • SM08502, a Novel, Small-Molecule CDC-like Kinase (CLK) Inhibitor, Demonstrates Strong Antitumor Effects and Wnt and Cyclin D-CDK4/6-RB Pathway Inhibition in Hormone-Receptor-Positive (HR+) Breast Cancer Models

European League Against Rheumatism (EULAR) | June 03 - 06

Virtual Meeting

  • Safety Profile of the Novel, Intra-articular Agent Lorecivivint (LOR; SM04690), a CLK/DYRK1A Inhibitor That Modulates the Wnt Pathway, in Subjects with Knee Osteoarthritis

  • The Novel, Intra-Articular CLK/DYRK1a Inhibitor Lorecivivint (LOR; SM04690), Which Modulates the Wnt Pathway, Improved Responder Outcomes in Subjects with Knee Osteoarthritis: A Post Hoc Analysis from a Phase 2b Trial

  • Items Driving WOMAC Pain Subscore Changes Due to Lorecivivint, a Potential Disease-Modifying Treatment for Knee Osteoarthritis: A Post Hoc Analysis of Phase 2b Trial Data

  • SM04755, a Potential Disease-Modifying Treatment for Tendinopathy, Modulates the Wnt Pathway via Inhibition of CLKs and DYRK1A

  • Lorecivivint (SM04690), an Intra-articular, Small-Molecule CLK/DYRK1A Inhibitor that Modulates the Wnt Pathway, as a Potential Treatment for Meniscal Injuries

  • Lorecivivint (SM04690), a Potential Disease-Modifying Treatment for Knee Osteoarthritis, Demonstrated Cartilage-Protective Effects on Human Osteoarthritic Explants

International Society for Pharmacoeconomics and Outcomes Research (ISPOR) | May 18 - 20

Virtual Meeting

  • Lorecivivint, a Potential Disease-Modifying Treatment for Knee Osteoarthritis: Factors Driving WOMAC Pain Subscore Changes - A Post Hoc Analysis of Phase 2b Data

Advances in Alzheimer’s and Parkinson’s Disease Therapies (AD/PD) Focus Meeting 2020 | April 02 - 05

Virtual Meeting

  • SM07883, a Novel, Potent, and Selective Oral DYRK1A Inhibitor, Reduces Neuroinflammatory Responses in Mouse Models

European Workshop for Rheumatology Research (EWRR) | February 13 - 15

Leuven, Belgium

  • Lorecivivint (SM04690), a Potential Disease-Modifying Treatment for Knee Osteoarthritis, Demonstrated Cartilage-Protective Effects on Human Osteoarthritic Explants

Tau2020 Global Conference | February 12 - 13

Washington, D.C

  • SM07883, a Novel, Oral DYRK1A Kinase Inhibitor, Reduced Tau Pathology and Associated Behavioral Deficits in Preclinical Models

Orthopaedic Research Society (ORS) | February 08 - 11

Phoenix, AZ

  • SM04755, a Potential Disease-Modifying Treatment for Tendinopathy, Modulates the Wnt Pathway via Inhibition of CLK2 and DYRK1A

2019

San Antonio Breast Cancer Symposium (SABCS) | December 10 - 14

San Antonio, TX

  • SM08502, a Novel, Small-Molecule CDC-like Kinase (CLK) Inhibitor, Demonstrates Strong Inhibition of the Wnt Signaling Pathway and Antitumor Effects as Monotherapy and in Combination with Chemotherapy in Triple-Negative Breast Cancer (TNBC) Models

American Society of Hematology (ASH) | December 07 - 10

San Diego, CA

  • SM09419, a Novel, Small-Molecule CDC-like Kinase (CLK) Inhibitor, Demonstrates Strong Inhibition of the Wnt Signaling Pathway and Antitumor Effects in Tumor Protein p53 (TP53)-Mutant Acute Myeloid Leukemia Models

  • SM09419, a Novel, Small-Molecule CDC-like Kinase (CLK) Inhibitor, Demonstrates Strong Inhibition of the Wnt Signaling Pathway and Antitumor Effects in Mantle Cell Lymphoma Models

  • SM09419, a Novel, Small-Molecule CDC-like Kinase (CLK) Inhibitor, Demonstrates Strong Inhibition of the Wnt Signaling Pathway and Antitumor Effects in FMS-like Tyrosine Kinase 3 (FLT3)-Mutant Acute Myeloid Leukemia Models

American College of Rheumatology (ACR) | November 08 - 13

Atlanta, GA

  • Subject Enrichment Criteria for Phase 3 Studies of Lorecivivint (SM04690), a Potential Disease-Modifying Knee Osteoarthritis Drug: A Post Hoc Study on the Effects of Baseline Comorbid Pain and Joint Space Width on Patient-Reported Outcomes

  • Safety Profile to Date of the Novel, Intra-articular Agent Lorecivivint (LOR; SM04690), a CLK/DYRK1A Inhibitor That Modulates the Wnt Pathway, in Subjects with Knee Osteoarthritis

  • The Novel, Intra-articular CLK/DYRK1A Inhibitor Lorecivivint (LOR; SM04690), Which Modulates the Wnt Pathway, Improved Responder Outcomes in Subjects with Knee Osteoarthritis: A Post Hoc Analysis from a Phase 2b Trial

  • Lorecivivint (SM04690), a Potential Disease-Modifying Osteoarthritis Drug, Inhibits CLK2 and DYRK1A, Novel Molecular Regulators of Wnt Signaling, Chondrogenesis, and Inflammation

Society for Neuroscience (SFN) | October 19 - 23

Chicago, IL

  • Tau Pathology Reduction with SM07883, a Novel, Potent, and Selective Oral DYRK1A Inhibitor

  • SM07883, a Novel, Oral DYRK1A Inhibitor, Improves Cognition and Protects Against Amyloid and Tau Pathologies in the 3xTg-AD Mouse Model of Alzheimer’s Disease

  • Anti-inflammatory Effects of SM07883, a Novel, Potent, and Selective Oral DYRK1A Inhibitor in Mouse Models of Neuroinflammation

World Congress on Controversies, Debates & Consensus in Bone, Muscle & Joint Diseases (BMJD) | October 17 - 19

Taipei, Taiwan

  • Prospective Comparison of Sham vs. Placebo Injections: Data from a Trial of Lorecivivint, a Wnt Pathway Inhibitor for Knee Osteoarthritis

  • Wnt Pathway Modulation via CLK2 and DYRK1A Inhibition by Lorecivivint, a Potential Disease-Modifying Treatment for Knee Osteoarthritis

  • Lorecivivint (SM04690): An Intra-articular Wnt Pathway Inhibitor for Knee Osteoarthritis Treatment – Phase 2b Patient-Reported Outcomes

  • Optimizing Subject Selection in Knee Osteoarthritis Trials by Joint Space Width: Analysis from a Phase 2b Trial of Lorecivivint (SM04690)

Cartilage Regeneration & Joint Preservation Society (ICRS) World Congress | October 05 - 08

Vancouver, Canada

  • Prospective Comparison of Sham vs. Placebo Injections: Data from a Trial of Lorecivivint, a Wnt Pathway Inhibitor for Knee Osteoarthritis

  • Wnt Pathway Modulation via CLK2 and DYRK1A Inhibition by Lorecivivint, a Potential Disease-Modifying Treatment for Knee Osteoarthritis

  • Optimizing Subject Selection in Knee Osteoarthritis Trials by Joint Space Width: Analysis from a Phase 2b Trial of Lorecivivint (SM04690)

  • Lorecivivint (SM04690): An Intra-articular Wnt Pathway Inhibitor for Knee Osteoarthritis Treatment – Phase 2b Patient-Reported Outcomes

American Association for Cancer Research (AACR) - Advances in Ovarian Cancer Research | September 13 - 16

Atlanta, GA

  • SM08502, a novel, small-molecule CDC-like kinase (CLK) inhibitor, demonstrates strong inhibition of the Wnt signaling pathway and antitumor effects in diverse ovarian cancer models

American Association for Cancer Research (AACR) - Pancreatic Cancer Meeting | September 06 - 09

Boston, MA

  • Inhibition of tumor growth and post-treatment regrowth by SM08502, a novel, small-molecule CDC-like kinase (CLK) inhibitor, in combination with standard of care in pancreatic cancer models

  • SM08502, a novel, small-molecule CDC-like kinase (CLK) inhibitor, demonstrates activity against cancer stem cell (CSC)-enriched pancreatic cancer cells and suppresses stemness in vitro

  • SM08502, a novel, small-molecule CDC-like kinase (CLK) inhibitor, downregulates the Wnt signaling pathway and demonstrates antitumor activity in pancreatic cancer cell lines and in vivo xenograft models

Gordon Research Conference (GRC) - Wnt Signaling Networks in Development, Disease and Regeneration | August 11 - 16

Mount Snow, VT

  • Lorecivivint (SM04690), a Potential Disease-Modifying Osteoarthritis Drug, Inhibits CLK2 and DYRK1A, Novel Molecular Regulators of Wnt Signaling, Chondrogenesis, and Inflammation

Alzheimer's Association International Conference (AAIC) | July 14 - 18

Los Angeles, CA

  • Anti-inflammatory Effects of SM07883, a Novel, Potent, and Selective Oral DYRK1A Inhibitor in Neurodegenerative Mouse Models

International Workshop on Osteoarthritis Imaging (IWOAI) | June 26 - 29

Prince Edward Island, Canada

  • Optimizing Subject Selection in Knee Osteoarthritis Clinical Trials by Radiographic Joint Space Width: Post Hoc Clinical Response Analysis from a Phase 2b Trial of Wnt Pathway Inhibitor SM04690

Keystone Symposia - Neurodegenerative Diseases: New Insights and Therapeutic Opportunities | June 16 - 20

Keystone, CO

  • SM07883, a Novel Oral DYRK1A Kinase Inhibitor, Reduced Tau, Amyloid Pathology, and Related Inflammation in Preclinical Models

European League Against Rheumatism (EULAR) | June 12 - 15

Madrid, Spain

  • Inhibition of CLK2 And DYRK1A by Lorecivivint (SM04690) as a Novel Molecular Regulator of Wnt Signaling, Chondrogenesis, and Inflammation, a Potential Disease-Modifying Treatment for Knee Osteoarthritis

  • Optimizing Subject Selection in Knee Osteoarthritis Clinical Trials by Radiographic Joint Space Width: Post Hoc Clinical Response Analysis from a Phase 2b Trial of Wnt Pathway Inhibitor Lorecivivint (SM04690)

  • Comparison of Intra-articular Sham and Vehicle Injections from a Phase 2b Trial of Lorecivivint (SM04690), a Small-Molecule Wnt Pathway Inhibitor for Knee Osteoarthritis

  • Efficacy and Safety from a Phase 2b Trial of Lorecivivint (SM04690), a Novel Intra-articular Wnt Pathway Inhibitor for the Treatment of Osteoarthritis of the Knee

  • Comparison of Knee Osteoarthritis Treatment Patterns by Rheumatologists vs. Other Providers in a U.S. Administrative Claims Database

American Society of Clinical Oncology (ASCO) | May 31 - Jun 04

Chicago, IL

  • Effects of SM08502, a Novel, Oral, Small-Molecule Inhibitor of Wnt Pathway Signaling, on Gene Expression and Antitumor Activity in Colorectal Cancer (CRC) Models

International Society for Pharmaeconomics and Outcomes Research (ISPOR) | May 18 - 22

New Orleans, LA

  • An Analysis of Treatment Patterns in Knee Osteoarthritis in a U.S. Administrative Claims Database

Osteoarthritis Research Society International (OARSI) World Congress | May 02 - 05

Toronto, Canada

  • Lorecivivint (SM04690), a Potential Disease-Modifying Treatment for Knee Osteoarthritis, Functions through Inhibition of CLK2 and DYRK1A, Novel Molecular Regulators of Wnt Signaling, Chondrogenesis, and Inflammation

  • Comparison of Intra-articular Sham and Vehicle Injection from a Phase 2b Trial of Lorecivivint (SM04690), a Small-Molecule Wnt Inhibitor, for Knee Osteoarthritis

  • Efficacy and Safety from a Phase 2b Trial of Lorecivivint (SM04690), a Novel Intra-articular Wnt Pathway Inhibitor for the Treatment of Osteoarthritis of the Knee

Pan-American League of Associations for Rheumatology (PANLAR) | April 27 - 30

Quito, Ecuador

  • Efficacy and Safety from a Phase 2b Trial of Lorecivivint (SM04690), a Novel, Intra-articular Wnt Pathway Inhibitor for the Treatment of Osteoarthritis of the Knee

World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases | April 04 - 07

Paris, France

  • Results from a Phase 2b Trial of SM04690, a Novel Intra-articular Wnt Pathway Inhibitor for the Treatment of Knee Osteoarthritis

  • Prospective Comparison of Intra-articular Sham vs. Placebo Injections: Data from a Randomized Controlled Phase 2b Trial of SM04690, a Wnt Pathway Inhibitor for Knee Osteoarthritis

  • Modulation of the Wnt Pathway through Inhibition of CLK2 and DYRK1A by SM04690, a Novel Potential Disease-Modifying Treatment for Knee Osteoarthritis

International Dermatology and Cosmetology Congress (INDERCOS) | March 27 - 30

Istanbul, Turkey

  • A small-molecule Wnt pathway modulator (SM04554) as a potential topical treatment for androgenetic alopecia

International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD) | March 26 - 31

Lisbon, Portugal

  • Cognitive Improvement and Protection Against Amyloid and Tau Pathology with SM07883, an Oral DYRK1A Inhibitor, in the 3xTG Mouse Model of Alzheimer’s Disease; Preliminary Results

Academy of Managed Care Pharmacy (AMCP) | March 25 - 28

San Diego, CA

  • An Analysis of the Burden of Illness and Treatment in Knee Osteoarthritis in a U.S. Administrative Claims Database

American Academy of Orthopaedic Surgeons (AAOS) | March 12 - 16

Las Vegas, NV

  • A 52-Week, Randomized, Double-Blind, Phase 2 Study of an Intra-articular Wnt Pathway Inhibitor (SM04690) for Osteoarthritis

Orthopaedic Research Society (ORS) | February 02 - 05

Austin, TX

  • SM04690, a Potential Disease-Modifying Treatment for Knee Osteoarthritis, Functions Through Inhibition of CLK2 and DYRK1A, Novel Molecular Regulators of Wnt Signaling, Chondrogenesis, and Inflammation

International Cartilage Regeneration & Joint Preservation Society (ICRS) Summit | January 17 - 18

San Diego, CA

  • Efficacy and Safety from a Phase 2b Trial of SM04690: A Novel, Intra-Articular Wnt Pathway Inhibitor for the Treatment of Knee Osteoarthritis

2018

New York Academy of Sciences (NYAS) Symposium on Alzheimer's Disease Therapeutics | December 11

New York, NY

  • Tau Pathology Reduction with SM07883, A Novel, Potent, and Selective Oral DYRK1A Inhibitor - Potential Therapeutic for Alzheimer’s Disease

International Conference on Frontotemporal Dementias | November 11 - 14

Sydney, Australia

  • SM07883, a Novel, Potent, and Selective Oral DYRK1A Inhibitor Reduced Tau Pathology in Preclinical Models

World Congress on Controversies, Debates & Consensus in Bone, Muscle & Joint Diseases (BMJD) | November 08 - 10

Bangkok, Thailand

  • SM04690, A Wnt Pathway Inhibitor: Anti-Inflammatory and Cartilage Protective Effects in Preclinical OA Models

  • Joint Space Width Criteria Can Reduce Knee Osteoarthritis Trial Heterogeneity: Phase 2 Post-Hoc Data from Wnt Pathway Inhibitor SM04690

  • Results from a 52-Week Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of a Novel, Wnt Pathway Inhibitor (SM04690) for Knee Osteoarthritis Treatment

  • Radiographic Outcomes Were Concordant with Pain and Function Response: Post-Hoc Analysis from a Phase 2 Study of SM04690, a Wnt Pathway Inhibitor for Knee Osteoarthritis Treatment

Clinical Trials on Alzheimer's Disease (CTAD) | October 24 - 27

Barcelona, Spain

  • SM07883, a novel DYRK1A inhibitor, reduced Tau pathology – discovery and preclinical development of a potential therapeutic for Alzheimer’s disease

American College of Rheumatology (ACR) | October 19 - 24

Chicago, IL

  • Efficacy and Safety from a Phase 2b Trial of SM04690, a Novel, Intra-Articular, Wnt Pathway Inhibitor for the Treatment of Osteoarthritis of the Knee

  • Experimental Tendinopathy Treatment with SM04755, a Topical Small Molecule Inhibitor of the Wnt Pathway

  • Treatment of Knee Osteoarthritis with SM04690 Improved WOMAC A1 “Pain on Walking” – Results from a 52-Week, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of a Novel, Intra-Articular, Wnt Pathway Inhibitor

  • Assessment of Health-Related Quality of Life in a 52-Week, Phase 2, Randomized, Controlled Trial of a Novel, Intra-Articular, Wnt Pathway Inhibitor (SM04690) for Treatment of Knee Osteoarthritis

Asia Pacific League of Associations for Rheumatology (APLAR) | September 06 - 09

Kaohsiung, Taiwan

  • Results from a 52-week, phase 2a study of an intra-articular, small molecule Wnt pathway inhibitor, SM04690, for knee osteoarthritis

Alzheimer’s Association International Conference (AAIC) | July 22 - 26

Chicago, IL

  • Tau Pathology Reduction with SM07883, a Novel, Potent, and Selective Oral DYRK1A Inhibitor - a Potential Therapeutic for Alzheimer’s Disease

International Workshop on Osteoarthritis Imaging (IWOAI) | July 05 - 07

Menton, France

  • Radiographic outcomes were associated with pain and function responses: post-hoc analysis from a phase 2 study of Wnt pathway inhibitor, SM04690, for knee osteoarthritis

European League Against Rheumatism (EULAR) | June 13 - 16

Amsterdam, Netherlands

  • Treatment of Knee Osteoarthritis with SM04690 Improved WOMAC A1 “Pain on Walking” – Results from a 52 week Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of a Novel, Intra-Articular, Wnt Pathway Inhibitor

  • Experimental Tendinopathy Treatment with SM04755, a Topical Small Molecule Inhibitor of the Wnt Pathway

  • Potential Nociceptive Pain Relief of Intra-Articular Saline Control in Clinical Trials of Knee Osteoarthritis: A Systematic Review and Meta-Analysis of Randomized Trials

  • Radiographic outcomes were associated with pain and function responses: post-hoc analysis from a phase 2 study of a Wnt pathway inhibitor, SM04690, for knee osteoarthritis treatment

  • Small Molecule Inhibitor of the Wnt Pathway (SM04755) as a Potential Topical Treatment for Psoriasis

  • SM04690, a WNT Pathway Inhibitor: Anti-Inflammatory and Cartilage Protective Effects in Preclinical OA Models

  • Results from a 52-Week Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of a Novel, Wnt Pathway Inhibitor (SM04690) for Knee Osteoarthritis Treatment

  • Adjusting for the Intra-Articular Placebo Effect in Knee Osteoarthritis Therapies

The Orthobiologic Institute (TOBI) Annual Symposium | June 07 - 09

Las Vegas, NV

  • Results from a 52-Week, Phase 2a Study of an Intra-Articular, Wnt Pathway Inhibitor, SM04690, for Knee Osteoarthritis

  • SM04690, a Wnt Pathway Inhibitor: Anti-Inflammatory and Cartilage Protective Effects in Preclinical OA Models

  • Preclinical Evidence for SM04690, a Small Molecule Wnt Pathway Inhibitor, as a Potential Treatment for Degenerative Disc Disease

  • A Small Molecule Inhibitor of the Wnt Pathway (SM04755) as a Potential Topical Treatment for Tendinopathy

  • Experimental Tendinopathy Treatment with SM04755, a Topical Small Molecule Wnt Pathway Inhibitor

American Thoracic Society (ATS) | May 18 - 23

San Diego, CA

  • SM04646 inhibited Wnt pathway gene expression stimulated in response to Transforming Growth Factor-β and was effective in a chronic model of Bleomycin-induced pulmonary fibrosis

International Investigative Dermatology (IID) | May 16 - 19

Orlando, FL

  • Small Molecule Wnt Pathway (SM04755) Inhibitor as a Potential Topical Treatment for Psoriasis

International Society for the Study of the Lumbar Spine (ISSLS) Annual Meeting | May 14 - 18

Banff, Canada

  • A Small Molecule Inhibitor of the Wnt Pathway (SM04690) as a Potential Treatment for Degenerative Disc Disease

Osteoarthritis Research Society International (OARSI) World Congress | April 26 - 29

Liverpool, United Kingdom

  • Experimental Tendinopathy Treatment with SM04755, a Topical Small Molecule Inhibitor of the Wnt Pathway

  • SM04690, a Wnt Pathway Inhibitor: Anti-Inflammatory and Cartilage Protective Effects in Preclinical Osteoarthritis Models

  • Radiographic Outcomes Were Concordant with Outcome Measures in Rheumatology Osteoarthritis Research Society International (OMERACT-OARSI) Strict Response: Post-Hoc Analysis from a Phase 2 Study of a Wnt Pathway Inhibitor, SM04690, for Knee Osteoarthritis Treatment

  • Joint Space Width Inclusion Criteria Can Reduce Knee Osteoarthritis Trial Heterogeneity: Post-Hoc Data from a Phase 2 Trial of Wnt Pathway Inhibitor, SM04690

  • Results from a 52-Week Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of a Novel, Intra-Articular Wnt Pathway Inhibitor (SM04690) for the Treatment of Knee Osteoarthritis

World Congress on Osteoporosis, Osteoarthritis, and Musculoskeletal Diseases | April 19 - 22

Krakow, Poland

  • Results from a 52 Week, Phase 2a Study of an Intra-Articular, Wnt Pathway Inhibitor, SM04690, for Knee Osteoarthritis

  • Joint Space Width Criteria Can Reduce Knee OA Trial Heterogeneity: Phase 2 Post-Hoc Data from Wnt Pathway Inhibitor, SM04690

  • SM04690, a Wnt Pathway Inhibitor: Anti-Inflammatory and Cartilage Protective Effects in Preclinical OA Models

  • SM04690, a small molecule Wnt pathway inhibitor, appeared to have no deleterious effects on bone, joint, and tissue health in knee OA models

  • SM04690 caused dose-dependent Wnt pathway modulation within a homeostatic range in a rat model of knee osteoarthritis

International Cartilage Repair Society (ICRS) | April 09 - 12

Macao, China

  • SM04690, a Wnt Pathway Inhibitor: Anti-Inflammatory and Cartilage Protective Effects in Preclinical OA Models

  • Radiographic Outcomes Were Concordant with Pain and Function Response: Post-Hoc Analysis from a Phase 2 Study of SM04690, a Wnt Pathway Inhibitor for Knee Osteoarthritis Treatment

  • Joint Space Width Criteria Can Reduce Knee OA Trial Heterogeneity: P2 Post-Hoc Data from Wnt Pathway Inhibitor, SM04690

  • A 52 Week Randomized, Double-Blind Phase 2 Study of Intra-Articular, Wnt Pathway Inhibitor (SM04690) for Osteoarthritis

Pan-American League of Associations for Rheumatology (PANLAR) | April 07 - 10

Buenos Aires, Argentina

  • Results from a 52-Week Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of a Novel, Intra-Articular Wnt Pathway Inhibitor (SM04690) for the Treatment of Knee Osteoarthritis

  • SM04690, a Wnt Pathway Inhibitor: Anti-Inflammatory and Cartilage Protective Effects in Preclinical OA Models

Advances in Alzheimer's and Parkinson's Therapies (AAT-AD/PD) Focus Meeting 2018 | March 15 - 18

Turin, Italy

  • Tau Pathology Reduction with SM07883, a Novel, Potent, and Selective Oral DYRK1A Inhibitor – a Potential Therapeutic for Alzheimer’s Disease

Orthopaedic Research Society (ORS) | March 10 - 13

New Orleans, LA

  • Anti-Inflammatory Properties of SM04690, a Small Molecule Inhibitor of the Wnt Pathway as a Potential Treatment for Knee Osteoarthritis

  • Experimental Tendinopathy Treatment with SM04755, a Topical Small Molecule Inhibitor of the Wnt Pathway

American Academy of Dermatology (AAD) | February 16 - 20

San Diego, CA

  • Small Molecule Inhibitor of the Wnt Pathway (SM04755) as a Potential Topical Treatment for Psoriasis

2017

Pulmonary Fibrosis Foundation Summit (PFF) | November 09 - 11

Nashville, TN

  • Discovery of a Small Molecule Inhibitor of the Wnt Pathway (SM04646) Delivered as an Inhaled Aerosol for the Treatment of Idiopathic Pulmonary Fibrosis (IPF)

American College of Rheumatology (ACR) | November 03 - 08

San Diego, CA

  • Results from a 52 Week Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of a Novel, Intra-Articular, Wnt Pathway Inhibitor (SM04690) for the Treatment of Knee Osteoarthritis

  • Reducing Heterogeneity in OA Clinical Trials: Data from a Phase 2 Study of SM04690, a Novel, Intra-Articular, Wnt Pathway
    Inhibitor in Knee Osteoarthritis

  • Radiographic Outcomes Were Associated with Pain and Function Responses: Post-Hoc Analysis of Results from a Phase 2 Study of a Small Molecule Wnt Pathway Inhibitor, SM04690, for Knee Osteoarthritis Treatment

Orthopaedic Research Society (ORS) Southern California Regional Symposium | September 25

Los Angeles, CA

  • Interim Results from a 52 week Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of a Novel, Intra-Articular, Wnt Pathway Inhibitor (SM04690) for the Treatment of Knee Osteoarthritis

  • Cartilage Regeneration in a Rat Model of Knee OA by SM04690, a Potential Disease Modifying Wnt Pathway Inhibitor

Gordon Research Conference: Wnt Signaling | August 06 - 11

Stowe, VT

  • Discovery of a Small Molecule Inhibitor of the Wnt Pathway (SM04690) as a Potential Disease Modifying Treatment for Knee Osteoarthritis

Spine Intervention Society (SIS) | July 19 - 22

San Francisco, CA

  • Discovery of a Small Molecule Wnt Pathway Inhibitor (SM04690) as a Potential Treatment for Degenerative Disc Disease

International Cartilage Repair Society Heritage Summit | June 29 - Jul 01

Gothenburg, Sweden

  • Cartilage Regeneration in a Rat Model of Knee OA by SM04690, a Potential Disease Modifying Wnt Pathway Inhibitor

European League Against Rheumatism (EULAR) | June 14 - 17

Madrid, Spain

  • Radiographic Outcomes from a Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of a Novel, Intra-Articular, Injectable, Wnt Inhibitor (SM04690) in the Treatment of Osteoarthritis of the Knee: Week 26 Interim Analysis

  • Clinical Outcomes from a Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of a Novel, Intra-Articular, Injectable, Wnt Pathway Inhibitor (SM04690) for the Treatment of Knee Osteoarthritis: Week 26 Interim Analysis

  • Discovery of a Small Molecule Inhibitor of the Wnt Pathway (SM04755) as a Potential Topical Treatment for Tendinopathy

  • Anti-inflammatory Properties of SM04690, a Small Molecule Inhibitor of the Wnt Pathway as a Potential Treatment for Knee Osteoarthritis

International Society for Pharmacoeconomics and Outcomes (ISPOR) | May 20 - 24

Boston, MA

  • Health Care Resource Use of Medicare Beneficiaries With Primary Osteoarthritis (OA) Of The Knee – A Claims Data Analysis

  • A Statistical Analysis Plan to Understand Osteoarthritis Patient Journey by Linking Medicare Claims Across Care Delivery Settings

American Thoracic Society (ATS) | May 19 - 24

Washington D.C.

  • Discovery of a Small Molecule Inhibitor of the Wnt pathway (SM04646) Delivered as an Inhaled Aerosol for the Treatment of Idiopathic Pulmonary Fibrosis (IPF)

Musculoskeletal Regenerative Medicine and Biology: From Development to Regeneration | May 04 - 06

St. Louis, MO

  • Discovery of a Small Molecule Wnt Pathway Inhibitor (SM04690) as a Potential Treatment for Degenerative Disc Disease

  • Discovery of a Small Molecule Inhibitor of the Wnt Pathway (SM04755) as a Potential Topical Treatment for Tendinopathy

  • Discovery of a Small Molecule Wnt Pathway Inhibitor (SM04690) as a Potential Disease Modifying Treatment for Knee Osteoarthritis

Osteoarthritis Research Society International (OARSI) | April 27 - 30

Las Vegas, NV

  • Discovery of a Small Molecule Inhibitor of the Wnt Pathway (SM04755) as a Potential Topical Treatment for Tendinopathy

  • Anti-inflammatory Properties of SM04690, a Small Molecule Inhibitor of the Wnt Pathway as a Potential Treatment for Knee Osteoarthritis

  • Discovery of a Small Molecule Inhibitor of the Wnt Pathway (SM04690) as a Potential Treatment for Degenerative Disc Disease

Society for Investigative Dermatology (SID) | April 26 - 29

Portland, OR

  • Small Molecule Inhibitor of the Wnt Pathway (SM04755) as a Potential Topical Scleroderma Treatment

  • Small Molecule Wnt Pathway Inhibitor (SM04755) as a Potential Topical Psoriasis Treatment

  • A Small Molecule Modulator of the Wnt Pathway (SM04554) as a Potential Topical Treatment for Androgenetic Alopecia (AGA)

World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases | March 23 - 26

Florence, Italy

  • Discovery of a Small Molecule Inhibitor of the Wnt Pathway (SM04755) as a Potential Topical Treatment for Tendinopathy

  • Discovery of a Small Molecule Wnt Pathway Inhibitor (SM04690) as a Potential Disease Modifying Treatment for Knee Osteoarthritis

  • Discovery of a Small Molecule Wnt Pathway Inhibitor (SM04690) as a Potential Treatment for Degenerative Disc Disease

Orthopaedic Research Society (ORS) | March 19 - 22

San Diego, CA

  • Discovery of a Small Molecule Inhibitor of the Wnt Pathway (SM04690) as a Potential Disease Modifying Treatment for Knee Osteoarthritis

  • Discovery of a Small Molecule Inhibitor of the Wnt Pathway (SM04755) as a Potential Topical Treatment for Tendinopathy

  • Discovery of a Small Molecule Inhibitor of the Wnt Pathway (SM04690) as a Potential Treatment for Degenerative Disc Disease

American Academy of Dermatology (AAD) | March 03 - 07

Orlando, FL

  • Safety and Biopsy Outcomes of a Topical Treatment (SM04554) for Male Androgenetic Alopecia (AGA): Results from a Phase 2, Multicenter, Randomized, Double-blind, Vehicle-controlled Trial

Musculoskeletal Development and Regeneration Conference (MDRC) | February 24 - 27

Cancun, Mexico

  • Discovery of a Small Molecule Inhibitor of the Wnt Pathway (SM04690) as a Potential Disease Modifying Treatment for Knee Osteoarthritis

2016

American College of Rheumatology (ACR) | November 11 - 16

Washington D.C.

  • Discovery of a Small Molecule Inhibitor of the Wnt Pathway (SM04755) As a Potential Topical Treatment for Chronic Tendinopathy

  • Discovery of a Small Molecule Inhibitor of the Wnt Pathway (SM04755) As a Potential Topical Treatment for Scleroderma

  • Discovery of a Small Molecule Inhibitor of the Wnt Pathway (SM04690) As a Potential Treatment for Degenerative Disc Disease

  • Radiographic Outcomes from a Randomized, Double-Blind, Placebo-Controlled, Phase 1 Study of a Novel, Intra-Articular, Injectable, Wnt Inhibitor (SM04690) in the Treatment of Osteoarthritis of the Knee

  • A Small Molecule, SM04690, Has Inhibitory Effects on the Wnt Pathway and Inflammation in Vitro, with Potential Implications for the Treatment of Osteoarthritis

  • Discovery of a Small Molecule Inhibitor of the Wnt Pathway (SM04755) As a Potential Topical Treatment for Psoriasis

  • Analysis of Pain and Function Components in Omeract-Oarsi Strict Responders from a Randomized, Double-Blind, Placebo-Controlled, Phase 1 Study of a Novel, Intra-Articular, Injectable, Wnt Inhibitor (SM04690) in the Treatment of Osteoarthritis of the Knee

International Cartilage Repair Society 2016 World Congress (ICRS) | September 24 - 27

Sorrento, Italy

  • Discovery of a Small Molecule Inhibitor of the Wnt Pathway (SM04690) as a Potential Disease Modifying Treatment for Knee Osteoarthritis

Royal Society of Medicine's 13th Medical Innovations Summit | September 17

London, United Kingdom

  • Samumed's Regenerative Medicine Platform

European League Against Rheumatism (EULAR) | June 08 - 11

London, United Kingdom

  • Safety, Clinical and Imaging Outcomes of a Novel, Intra-Articular, Injectable, Wnt Inhbitor (SM04690) in the Treatment of Osteoarthritis of the Knee: Exploratory Analysis of Results from a 24 week, Randomized, Double-Blind, Placebo-Controlled Phase 1 Study

  • Discovery of a Small Molecule Inhibitor of the Wnt Pathway (SM04690) as a Potential Disease Modifying Treatment for Knee Osteoarthritis

Osteoarthritis Research Society International (OARSI) | March 31 - Apr 03

Amsterdam, Netherlands

  • OMERACT-OARSI ‘Strict Responders’ Analysis from Results of a Randomized, Double-Blind, Placebo-Controlled Phase 1 Study of a Novel, Intra-Articular, Injectable Wnt Inhibitor (SM04690) in the Treatment of Osteoarthritis of the Knee

  • Discovery of a Small Molecule Inhibitor of the Wnt Pathway (SM04690) as a Potential Disease Modifying Treatment for Knee Osteoarthritis

American Academy of Dermatology (AAD) | March 04 - 08

Washington D.C.

  • Safety and Efficacy of a Topical Treatment (SM04554) for Androgenetic Alopecia (AGA): Results from a Phase 1 Trial

  • Safety, Tolerability and Efficacy of a Topical Treatment (SM04554) for Androgenetic Alopecia (AGA): Results from a Phase 2 Trial

2015

World Congress for Hair Research (WCHR) | November 18 - 21

Miami, FL

  • Safety and Efficacy of a Topical Treatment (SM04554) for Androgenetic Alopecia (AGA): Results from a Phase 1 Trial

American College of Rheumatology (ACR) | November 06 - Oct 11

San Francisco, CA

  • Safety, Efficacy and Biomarker Outcomes of a Novel, Intra-Articular, Injectable, Wnt Inhibitor (SM04690) in the Treatment of Osteoarthritis of the Knee: Interim, Exploratory Analysis of Results from a Randomized, Double-Blind, Placebo-Controlled Phase 1 Study

  • Magnetic Resonance Imaging Outcomes Using an Intra-Articular Injection (SM04690) in the Treatment of Osteoarthritis of the Knee: Interim, Exploratory Analysis of Results from a Randomized, Double-Blind, Placebo-Controlled, Phase 1 Study

  • Discovery of an Intra-Articular Injection Small Molecule Inhibitor of the Wnt Pathway (SM04690) As a Potential Disease Modifying Treatment for Knee Osteoarthritis

Award Winning

Privacy Policy Terms of use Contact Us © Samumed, LLC. All rights reserved